61 related articles for article (PubMed ID: 1803608)
41. Multivariate survival analysis using Cox's regression model.
Christensen E
Hepatology; 1987; 7(6):1346-58. PubMed ID: 3679094
[No Abstract] [Full Text] [Related]
42. Time-dependency in Cox's regression analysis.
Mulder PG
J Chronic Dis; 1987; 40(4):365-6. PubMed ID: 3558712
[No Abstract] [Full Text] [Related]
43. [Prognostic significance of some clinical and laboratory parameters in patients with chronic myelogenous leukemia].
Sledziowski P; Lisiewicz J
Przegl Lek; 1995; 52(2):42-6. PubMed ID: 7784614
[TBL] [Abstract][Full Text] [Related]
44. [The prognostic factors in chronic myeloleukemia].
Khoroshko ND
Ter Arkh; 1993; 65(7):23-8. PubMed ID: 8211773
[TBL] [Abstract][Full Text] [Related]
45. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
46. Multivariate analysis of prognostic factors in chronic myelogenous leukemia.
Jootar S; Chuncharunee S; Ongphiphaphadhanakul B; Atichartakarn V
J Med Assoc Thai; 1990 Dec; 73(12):662-9. PubMed ID: 2086713
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
48. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.
Hasford J; Pfirrmann M; Hehlmann R; Baccarani M; Guilhot F; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Thaler J; Steegmann JL;
Semin Hematol; 2003 Jan; 40(1):4-12. PubMed ID: 12563607
[TBL] [Abstract][Full Text] [Related]
49. [Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification].
Sacha T; Dulak J; Skotnicki AB; Dembińska-Kiec A
Przegl Lek; 1999; 56 Suppl 1():57-61. PubMed ID: 10494184
[TBL] [Abstract][Full Text] [Related]
50. [The prognostic assessment of patient survival in chronic myeloleukemia].
Petukhov VI; Bondar' DK; Rastrigin VL
Ter Arkh; 1991; 63(12):73-7. PubMed ID: 1803608
[TBL] [Abstract][Full Text] [Related]
51. The cytogenetic response as a surrogate marker of survival.
Rosti G; Testoni N; Martinelli G; Baccarani M
Semin Hematol; 2003 Apr; 40(2 Suppl 2):56-61. PubMed ID: 12783377
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
